Background
Mucopolysaccharidosis type I (MPS I) Hurler syndrome is a rare lysosomal storage disorder caused by the deficiency of the enzyme alpha-L-iduronidase, leading to the accumulation of glycosaminoglycans. The putative target P35475, also known as alpha-L-iduronidase, presents a potential therapeutic candidate for further investigation in the context of MPS I Hurler syndrome. Given its role in the disease's pathology, understanding its expression profile may provide insights into novel therapeutic strategies.Data-mining rationale
The identification of P35475 as a putative target was facilitated by a cross-referencing approach involving UniProt's reviewed human entries for "MPS I Hurler syndrome" against two microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Specifically, the datasets GDS:200193583 and GDS:200078889 were analyzed to assess gene expression patterns associated with the disease. Notably, P35475 emerged in expression-profiling studies but currently lacks a registered Phase 1 or higher clinical program, indicating a gap in its therapeutic exploration.Why prior analyses may have missed this
Many of the GEO datasets utilized in this analysis predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing corrections. As a result, previous analyses may not have accurately captured the differential expression of genes relevant to MPS I Hurler syndrome, potentially overlooking significant candidates like P35475. Re-analysis of these datasets using contemporary statistical approaches could yield more reliable insights into the expression dynamics of this putative target.Reasoning for further validation
To substantiate the potential of P35475 as a therapeutic target for MPS I Hurler syndrome, several experimental steps are warranted:1. Re-analyze the matched GEO datasets using the limma package, applying the Benjamini-Hochberg method for false discovery rate (FDR) correction with a threshold of < 0.05. 2. Validate the top differentially-expressed genes identified in the re-analysis by conducting quantitative PCR (qPCR) in an independent cohort to confirm expression changes. 3. Investigate the tissue specificity of P35475 expression using data from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to understand its relevance in various biological contexts. 4. Utilize pathway analysis tools such as STRING or OmniPath to explore the biological pathways associated with P35475 and its potential interactions with other proteins. 5. If validation is achieved, assess the druggability of P35475 through databases like DGIdb and ChEMBL to evaluate its potential as a drug target.